Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated with Radioactive Iodine for Thyroid Cancer
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Aug 13, 2023
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using artificial tears can help prevent a condition called nasolacrimal duct obstruction in patients who are receiving radioactive iodine therapy for thyroid cancer. This treatment can sometimes lead to blockage in the tear ducts due to inflammation caused by the radioactive material. The researchers want to see if using artificial tears regularly after the treatment can reduce the chances of developing this blockage over the next two years.
To participate in this study, you must be at least 18 years old and have received a specific amount of radioactive iodine therapy for thyroid cancer. However, some individuals, such as those who have had previous issues with their tear ducts or are currently using other types of eye drops, may not be eligible. If you join the study, you will likely be asked to use artificial tears as directed, and you’ll be monitored over time to see if this helps in preventing tear duct problems. This study is currently recruiting participants, and it aims to provide valuable information that could improve care for future patients undergoing similar treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Radio-iodine therapy for thyroid cancer
- • 2. Radioiodine therapy ≥150 mCi
- • 3. Age 18 or older
- Exclusion Criteria:
- • 1. Use of eye drops, other than artificial tears
- • 2. History of periocular trauma with tear duct involvement/lacrimal gland trauma
- • 3. History of lacrimal drainage disease: canaliculitis, dacryocystitis
- • 4. Prior radiotherapy
- • 5. Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
- • 6. Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)
- • 7. Nasolacrimal duct obstruction at baseline
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported